Ironwood Pharmaceuticals, Inc

Ironwood Pharmaceuticals is a U.S.-based biopharmaceutical company focused on gastrointestinal therapies. Its core business is the commercialization of LINZESS in the U.S. through a collaboration with AbbVie, while it also develops apraglutide for short bowel syndrome and evaluates additional GI opportunities.

33,6 %

8,1 %

−15,7 %

1.13

1.13

— Ironwood Pharmaceuticals, Inc
%
Commercialized GI therapy75% Revenue tied to LINZESS commercialization in the U.S. through a collaboration with AbbVie.
Pipeline development programs15% Clinical development of apraglutide and other GI product candidates.
Collaborative arrangements and royalties10% License fees, milestones, and royalties from linaclotide partnerships outside the U.S.

Ironwood sells primarily through a partner-led pharmaceutical model rather than direct end-customer sales...

  • AbbVie collaboration partnerprimary

    AbbVie commercializes LINZESS in the U.S. and shares net profits/losses with Ironwood.

  • Gastroenterology patients and prescribersprimary

    Patients and physicians using LINZESS for GI indications drive underlying product demand.

  • International licenseessecondary

    Partners in Europe, Canada, Mexico, Japan, China and other markets pay royalties and fees on linaclotide.

  • Clinical development stakeholderssecondary

    Regulators, investigators, and CDMOs support apraglutide development and approval efforts.

Ironwood is headquartered in the United States but now also has operations in Switzerland following the VectivBio...

  • •U.S. is the main revenue market for LINZESS
  • •Basel, Switzerland remains a key foreign operating base
  • •Europe, Canada, Mexico, Japan and China matter for linaclotide royalties
  • •Foreign operations add currency, regulatory, and data privacy exposure

Ironwood is concentrating on GI therapeutics, using LINZESS cash flows to support pipeline development and selective...

01
Protect and extend LINZESS economicsshort-term

LINZESS remains the main revenue engine, so pricing, reimbursement, and partner execution are critical.

02
Advance apraglutide developmentmedium-term

Apraglutide is the main pipeline asset and could diversify revenue beyond LINZESS if approved.

03
Evaluate strategic alternativesshort-term

Management is assessing options to maximize shareholder value amid pipeline and market uncertainty.

Ironwood is highly exposed to dependence on LINZESS and on AbbVie’s commercialization performance, so pricing pressure...

high

Dependence on LINZESS and AbbVie collaboration

Most revenue comes from U.S. LINZESS economics and settlement payments with AbbVie.

Scope
U.S. commercial performance and partner execution
Materiality
high
high

Drug pricing and reimbursement reform

Government action on pricing could lower realized net prices and profitability.

Scope
U.S. and OECD pricing policy
Materiality
high
high

Apraglutide clinical and regulatory uncertainty

FDA indicated a confirmatory Phase III trial is needed before NDA approval.

Scope
Pipeline development
Materiality
high
high

Manufacturing and supply chain reliance on third parties

Ironwood has no internal manufacturing or distribution capabilities.

Scope
API, fill-finish, packaging, and distribution
Materiality
high
medium

Foreign jurisdiction operating risk

Switzerland and other non-U.S. activities create currency, legal, and compliance exposure.

Scope
Basel and international operations
Materiality
medium
Revenue recognition for collaborations and licenses
Can shift revenue between periods and affect comparability
Sales reserves and rebate estimates
Can materially change collaboration revenue and net sales
Net profit share accounting for LINZESS
Quarterly volatility in revenue and operating margin
Debt and financing cost accounting
Affects net income and cash flow presentation

IRONWOOD PHARMACEUTICALS INC

IRWD · Pharmaceutical Preparations

Dogwood Therapeutics, Inc.

DWTX · Pharmaceutical Preparations

ARROWHEAD PHARMACEUTICALS, INC.

ARWR · Pharmaceutical Preparations

InspireMD, Inc.

NSPR · Surgical & Medical Instruments & Apparatus

IMMUNIC, INC.

IMUX · Pharmaceutical Preparations

LEXICON PHARMACEUTICALS, INC.

LXRX · Pharmaceutical Preparations

: 28.4.2026